Importance Major depressive disorder (MDD) is a substantial public health burden, but current
treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or …

There has recently been a renewal of human research with classical hallucinogens (psychedelics).
This paper first briefly discusses the unique history of human hallucinogen research, …

A large body of evidence, including longitudinal analyses of personality change, suggests
that core personality traits are predominantly stable after age 30. To our knowledge, no study …

Cancer patients often develop chronic, clinically significant symptoms of depression and
anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in …

Rationale This dose-effect study extends previous observations showing that psilocybin can
occasion mystical-type experiences having persisting positive effects on attitudes, mood, …

Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of
substance use disorders, rigorous follow-up has not been conducted. To determine the …

A within‐subject design, using human participants, compared delay discounting functions
for real and hypothetical money rewards. Both real and hypothetical rewards were studied …

Psilocybin has been used for centuries for religious purposes; however, little is known
scientifically about its long-term effects. We previously reported the effects of a double-blind study …

Research has found that nicotine-dependent individuals delay discount monetary gains at a
higher rate than matched controls. Delay discount rates, however, have also been found to …

Background: Preliminary data suggest that psilocybin-assisted treatment produces substantial
and rapid antidepressant effects in patients with major depressive disorder (MDD), but …